Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reducing lung cancer risk: early detection.

J L Mulshine1

  • 1Department of Cell and Cancer Biology, Medicine Branch, Division of Clinical Science, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1906, USA. mulshinej@bprb.nci.nih.gov

Chest
|January 5, 2000
PubMed
Summary

Improving lung cancer prognosis requires early detection strategies, including novel biomarkers like heterogeneous nuclear ribonucleoprotein. Effective chemoprevention and targeted drug delivery are crucial for managing airway-confined lung cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026
Same author

The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2007
Same author

Lung cancer screening: panacea or pipe dream?

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

Lung cancer. 2: screening and early diagnosis of lung cancer.

Thorax·2002
Same author

IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001.

Lung cancer (Amsterdam, Netherlands)·2002
Same author

Moving to the routine management of pre symptomatic lung cancer.

Lung cancer (Amsterdam, Netherlands)·2001

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Cancer Prevention

Background:

  • Lung cancer has a poor prognosis, necessitating improved early detection methods.
  • Biomarker identification for preclinical disease is key to multimodal cancer prevention strategies.
  • Current strategies focus on improving sensitivity and specificity for mass screening.

Purpose of the Study:

  • To investigate strategies for early lung cancer detection.
  • To explore the potential of biomarkers for preclinical lung cancer identification.
  • To evaluate chemoprevention and direct drug delivery methods for airway-confined lung cancer.

Main Methods:

  • Identification of potential early disease markers, such as heterogeneous nuclear ribonucleoprotein.
  • Investigation of multimodal cancer prevention strategies.

Related Experiment Videos

  • Exploration of direct drug delivery, including aerosolized retinoids.

    • Main Results:

    • Heterogeneous nuclear ribonucleoprotein identified as a potential marker for early lung cancer.
    • Multiple markers may be required for sensitive and specific mass screening.
    • Direct drug delivery aims to maximize efficacy and minimize systemic side effects.

    Conclusions:

    • Early detection of lung cancer is critical for improving patient outcomes.
    • Biomarker discovery and chemoprevention are essential components of lung cancer management.
    • Targeted drug delivery offers a promising approach for treating early-stage, airway-confined lung cancer.